🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to scientists.

A Global Challenge

Gonorrhoea infections are increasing around the world, with figures suggesting more than 82 million instances each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, the spread of superbugs and the highly restricted treatment choices at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Outcomes and Global Access

As per findings detailed in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which uses two antibiotics. The research involved over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals on the front lines have voiced hope. Access to a single-dose, oral treatment such as this is hailed as a "revolutionary step" for public health efforts. This is viewed as vital to lessen the impact of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.